AR076511A1 - Composicion farmaceutica en lipidos estabilizada de un promotor de la apoptosis. uso. - Google Patents
Composicion farmaceutica en lipidos estabilizada de un promotor de la apoptosis. uso.Info
- Publication number
- AR076511A1 AR076511A1 ARP100101469A ARP100101469A AR076511A1 AR 076511 A1 AR076511 A1 AR 076511A1 AR P100101469 A ARP100101469 A AR P100101469A AR P100101469 A ARP100101469 A AR P100101469A AR 076511 A1 AR076511 A1 AR 076511A1
- Authority
- AR
- Argentina
- Prior art keywords
- composition
- formula
- pharmaceutically acceptable
- compound
- antioxidant
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000006907 apoptotic process Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 14
- -1 azepan-1-yl Chemical group 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 239000003963 antioxidant agent Substances 0.000 abstract 5
- 230000003078 antioxidant effect Effects 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 5
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052801 chlorine Inorganic materials 0.000 abstract 4
- 239000000460 chlorine Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 229910052731 fluorine Chemical group 0.000 abstract 4
- 239000011737 fluorine Chemical group 0.000 abstract 4
- JLYAXFNOILIKPP-KXQOOQHDSA-N navitoclax Chemical compound C([C@@H](NC1=CC=C(C=C1S(=O)(=O)C(F)(F)F)S(=O)(=O)NC(=O)C1=CC=C(C=C1)N1CCN(CC1)CC1=C(CCC(C1)(C)C)C=1C=CC(Cl)=CC=1)CSC=1C=CC=CC=1)CN1CCOCC1 JLYAXFNOILIKPP-KXQOOQHDSA-N 0.000 abstract 4
- 229950004847 navitoclax Drugs 0.000 abstract 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 3
- 229910052794 bromium Inorganic materials 0.000 abstract 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052740 iodine Inorganic materials 0.000 abstract 3
- 239000011630 iodine Substances 0.000 abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 239000000539 dimer Substances 0.000 abstract 2
- 239000012458 free base Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 230000003381 solubilizing effect Effects 0.000 abstract 2
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 102000051485 Bcl-2 family Human genes 0.000 abstract 1
- 108700038897 Bcl-2 family Proteins 0.000 abstract 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 229910052798 chalcogen Inorganic materials 0.000 abstract 1
- 150000001787 chalcogens Chemical class 0.000 abstract 1
- 239000002738 chelating agent Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 150000002334 glycols Chemical class 0.000 abstract 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 229940057917 medium chain triglycerides Drugs 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 101150009274 nhr-1 gene Proteins 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229910052711 selenium Inorganic materials 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicacion 1: Una composicion farmacéutica para suministrar en forma oral caracterizada porque comprende (a) un compuesto de formula (1) donde X3 es cloro o fluor; y (i) X4 es azepan-1-ilo, morfolin-4-ilo, 1,4-oxazepan-4-ilo, pirrolidin-1-ilo, N(CH3)2, N(CH3)(CH(CH3)2), 7-azabiciclo[2.2.1]heptan-1-ilo o 2-oxa-5-azabiciclo[2.2.1] hept-5-ilo; y R0 es un resto de formula (2), donde X5 es CH2, C(CH3)2 o CH2CH2; X6 y X7 son ambos hidrogeno o ambos metilo; y X8 es fluor, cloro, bromo o yodo; o (ii) X4 es azepan-1-ilo, morfolin-4-ilo, pirrolidin-1-ilo, N(CH3)(CH(CH3)2) o 7-azabiciclo[2.2.1]heptan-1-ilo; y R0 es un resto de formula (3), donde X6, X7 y X8 son segun se dijo anteriormente; o (iii) X4 es morfolin-4-ilo o N(CH3)2; y R0 es un resto de formula (4), donde X8 es segun se dijo anteriormente; o una sal farmacéuticamente aceptable, una prodroga, la sal de una prodroga o un metabolito de la misma; (b) un antioxidante calcogeno más pesado farmacéuticamente aceptable; y (c) un vehículo lípido farmacéuticamente aceptable sustancialmente no acuoso; donde dicho compuesto y el antioxidante están formando una solucion en el vehículo lípido. Reivindicacion 4: La composicion de cualquiera de las reivindicaciones 1 - 3, caracterizada porque, en el compuesto de formula (1), R0 es un resto de formula (2) donde X5 es O, CH2, C(CH3)2 o CH2CH2; X6 y X7 son ambos hidrogeno o ambos metilo; y X8 es fluor, cloro, bromo o yodo. Reivindicacion 5: La composicion de cualquiera de las reivindicaciones 1 - 3, caracterizada porque, en el compuesto de formula (1), R0 es un resto de formula (5) donde X5 es O, CH2, C(CH3)2 o CH2CH2; X6 y X7 son ambos hidrogeno o ambos metilo; y X8 es fluor, cloro, bromo o yodo. Reivindicacion 8: La composicion de la reivindicacion 7, caracterizada porque el compuesto es la base libre de ABT-263 o ABT-263 di-HCI. Reivindicacion 10: La composicion de cualquiera de las reivindicaciones 1 - 9, caracterizada porque el antioxidante comprende uno o más compuestos antioxidantes de formula (6) donde n es 0, 1 o 2; Y1 es S o Se; Y2 es NHR1, OH o H, donde R1 es alquilo o alquilcarbonilo; Y3 es COOR2 o CH2OH, donde R2 es H o alquilo; y R3 es H o alquilo; donde los grupos alquilo opcionalmente están sustituidos de manera independiente con uno o más sustituyentes que se seleccionan independientemente entre el grupo que consiste en carboxilo, alquilcarbonilo, alcoxicarbonilo, amino y alquilcarbonilamino; una sal farmacéuticamente aceptable de los mismos; o, donde Y1 es S y R3 es H, un dímero -S-S- de los mismos o una sal farmacéuticamente aceptable de dicho dímero. Reivindicacion 14: La composicion de cualquiera de las reivindicaciones 1 - 13, caracterizada porque el vehículo comprende un fosfolípido y un componente solubilizante. Reivindicacion 16: La composicion de la reivindicacion 14 o la reivindicacion 15, caracterizada porque el componente solubilizante del vehículo comprende uno o más glicoles, glicolidos y/o materiales glicéridos. Reivindicacion 17: La composicion de la reivindicacion 14 o la reivindicacion 15, caracterizada porque el agente solubilizante comprende uno o más triglicéridos de cadena media. Reivindicacion 19: La composicion de cualquiera de las reivindicaciones 14 - 18, caracterizada porque además comprende un tensioactivo no fosfolípido. Reivindicacion 24: La composicion de la reivindicacion 22 o la reivindicacion 23, caracterizada porque el antioxidante poco soluble en lípidos se selecciona entre el grupo que consiste en sulfitos, bisulfitos, metabisulfitos, tiosulfatos y mezclas de los mismos. Reivindicacion 27: La composicion de la reivindicacion 26, caracterizada porque el agente quelante comprende EDTA o un sal del mismo. Reivindicacion 32: Uso de una composicion de cualquiera de las reivindicaciones 1 - 31 caracterizado porque es para tratar una enfermedad caracterizada por disfuncion apoptotica y/o sobreexpresion de una proteína antiapoptotica de la familia Bcl-2, administrando en forma oral una cantidad terapéuticamente efectiva de la composicion a un sujeto que padece la enfermedad. Reivindicacion 33: El uso de la reivindicacion 32, caracterizado porque la enfermedad es una enfermedad neoplásica. Reivindicacion 38: El uso de cualquiera de las reivindicaciones 32 - 37, caracterizado porque la composicion que se administra comprende base libre de ABT-263 o ABT-263 di-HCI.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17429909P | 2009-04-30 | 2009-04-30 | |
US28925409P | 2009-12-22 | 2009-12-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR076511A1 true AR076511A1 (es) | 2011-06-15 |
Family
ID=42732293
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP100101469A AR076511A1 (es) | 2009-04-30 | 2010-04-30 | Composicion farmaceutica en lipidos estabilizada de un promotor de la apoptosis. uso. |
Country Status (24)
Country | Link |
---|---|
US (1) | US8728516B2 (es) |
EP (1) | EP2424499A1 (es) |
JP (1) | JP5788869B2 (es) |
KR (1) | KR20120027283A (es) |
CN (1) | CN102802605B (es) |
AR (1) | AR076511A1 (es) |
AU (1) | AU2010242926B2 (es) |
BR (1) | BRPI1014492A8 (es) |
CA (1) | CA2758596A1 (es) |
CL (1) | CL2011002652A1 (es) |
CO (1) | CO6470833A2 (es) |
DO (1) | DOP2011000325A (es) |
EC (1) | ECSP11011491A (es) |
IL (1) | IL215474A (es) |
MX (1) | MX2011011525A (es) |
MY (1) | MY160603A (es) |
NZ (1) | NZ596047A (es) |
PE (1) | PE20120642A1 (es) |
RU (1) | RU2530642C2 (es) |
SG (1) | SG175145A1 (es) |
TW (2) | TW201100125A (es) |
UY (1) | UY32601A (es) |
WO (1) | WO2010127193A1 (es) |
ZA (1) | ZA201107594B (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100280031A1 (en) * | 2009-04-30 | 2010-11-04 | Paul David | Lipid formulation of apoptosis promoter |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US8362013B2 (en) * | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
TWI540132B (zh) * | 2009-06-08 | 2016-07-01 | 亞培公司 | Bcl-2族群抑制劑之口服醫藥劑型 |
TWI532484B (zh) * | 2009-06-08 | 2016-05-11 | 艾伯維有限公司 | 包含凋亡促進劑之固態分散劑 |
RU2551376C2 (ru) * | 2009-09-20 | 2015-05-20 | Эббви Инк. | Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2 |
SG10201500152UA (en) * | 2009-12-22 | 2015-03-30 | Abbvie Inc | Abt-263 capsule |
UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
US8716363B2 (en) * | 2011-09-28 | 2014-05-06 | Globus Medical, Inc. | Biodegradable putty compositions and implant devices, methods, and kits relating to the same |
AU2017227516B2 (en) * | 2016-03-02 | 2022-03-03 | Medivir Aktiebolag | Combination therapy with sorafenib or regorafenib and a phosphoramidate prodrug of troxacitabine |
CN112552348B (zh) * | 2019-09-26 | 2023-03-17 | 北京桦冠生物技术有限公司 | 含硒化合物及其制备和应用 |
WO2021092470A1 (en) * | 2019-11-08 | 2021-05-14 | Retina Foundation Of The Southwest | Compounds and implants for treating ocular disorders |
CN110963954A (zh) * | 2019-12-16 | 2020-04-07 | 武汉轻工大学 | 一种硒代蛋氨酸衍生物的合成方法及硒代蛋氨酸制品 |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5665379A (en) * | 1990-09-28 | 1997-09-09 | Pharmacia & Upjohn Aktiebolag | Lipid particle forming matrix, preparation and use thereof |
US5536729A (en) | 1993-09-30 | 1996-07-16 | American Home Products Corporation | Rapamycin formulations for oral administration |
IL111004A (en) | 1993-09-30 | 1998-06-15 | American Home Prod | Oral formulations of rapamycin |
AU692506B2 (en) | 1993-11-17 | 1998-06-11 | Ibah, Inc. | Transparent liquid for encapsulated drug delivery |
US5759548A (en) | 1993-11-30 | 1998-06-02 | Lxr Biotechnology Inc. | Compositions which inhibit apoptosis, methods of purifying the compositions and uses thereof |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5538737A (en) | 1994-11-30 | 1996-07-23 | Applied Analytical Industries, Inc. | Oral compositions of H2 -antagonists |
BE1009856A5 (fr) | 1995-07-14 | 1997-10-07 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule. |
US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
BE1011899A6 (fr) | 1998-04-30 | 2000-02-01 | Ucb Sa | Compositions pharmaceutiques gelifiables utilisables. |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
DE19913692A1 (de) | 1999-03-25 | 2000-09-28 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
DE19929361A1 (de) | 1999-06-25 | 2001-01-04 | Basf Ag | Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen |
US20030236236A1 (en) | 1999-06-30 | 2003-12-25 | Feng-Jing Chen | Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs |
US6309663B1 (en) | 1999-08-17 | 2001-10-30 | Lipocine Inc. | Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents |
US20060183776A9 (en) | 2000-03-03 | 2006-08-17 | Eisai Co., Ltd. | Liquid dosage formulations of donepezil |
US20020055631A1 (en) | 2000-09-20 | 2002-05-09 | Augeri David J. | N-acylsulfonamide apoptosis promoters |
AR031130A1 (es) | 2000-09-20 | 2003-09-10 | Abbott Lab | N-acilsulfonamidas promotoras de la apoptosis |
US6720338B2 (en) * | 2000-09-20 | 2004-04-13 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
BR0116845A (pt) * | 2001-01-31 | 2004-02-25 | Pfizer Prod Inc | Derivados éter úteis como inibidores de isozimas pde4 |
US20030105144A1 (en) * | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
DE60332212D1 (de) | 2002-02-04 | 2010-06-02 | Elan Pharma Int Ltd | Arzneistoffnanopartikel mit lysozym-oberflächenstabilisator |
WO2003072139A1 (en) | 2002-02-26 | 2003-09-04 | Astrazeneca Ab | Pharmaceutical formulation of iressa comprising a water-soluble cellulose derivative |
PE20030828A1 (es) * | 2002-03-04 | 2003-11-04 | Novartis Ag | Composicion oftalmica que comprende ascomicina |
US7030115B2 (en) * | 2002-03-21 | 2006-04-18 | Abbott Laboratories | N-sulfonylurea apoptosis promoters |
MY129850A (en) | 2002-04-29 | 2007-05-31 | Merck Sharp & Dohme | Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity |
EP1575569B1 (en) * | 2002-12-13 | 2010-09-29 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
US20060177430A1 (en) | 2002-12-20 | 2006-08-10 | Chakshu Research Inc | Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer |
US7973161B2 (en) | 2003-11-13 | 2011-07-05 | Abbott Laboratories | Apoptosis promoters |
WO2005049593A2 (en) | 2003-11-13 | 2005-06-02 | Abbott Laboratories | N-acylsulfonamide apoptosis promoters |
US7790190B2 (en) | 2004-03-20 | 2010-09-07 | Yasoo Health, Inc. | Aqueous emulsions of lipophile solubilized with vitamin E TPGS and linoleic acid |
FR2875409B1 (fr) | 2004-09-17 | 2010-05-07 | Sanofi Aventis | Composition pharmaceutique comprenant une dispersion solide a matrice polymere comprenant une phase continue de polydextrose et une phase continue d'un polymere autre que du polydextrose |
TWI337608B (en) | 2005-05-12 | 2011-02-21 | Abbott Lab | Apoptosis promoters |
CN1706371B (zh) | 2005-05-27 | 2010-11-10 | 沈阳药科大学 | 一种高效的马蔺子素制剂及其制备方法 |
WO2007043057A2 (en) | 2005-10-11 | 2007-04-19 | Yissum, Research Development Company Of The Hebrew University Of Jerusalem | Compositions for nasal delivery |
CN101346128B (zh) * | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
EP2037912A2 (en) | 2006-05-15 | 2009-03-25 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist |
EP1880715A1 (en) | 2006-07-19 | 2008-01-23 | Abbott GmbH & Co. KG | Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same |
JP5277168B2 (ja) | 2006-09-05 | 2013-08-28 | アボット・ラボラトリーズ | 血小板過剰を治療するbclインヒビター |
CA2664697A1 (en) * | 2006-09-28 | 2008-04-10 | Follica, Inc. | Methods, kits, and compositions for generating new hair follicles and growing hair |
WO2008064116A2 (en) | 2006-11-16 | 2008-05-29 | Abbott Laboratories | Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection |
WO2008124878A1 (en) | 2007-04-13 | 2008-10-23 | Cryptopharma Pty Ltd | Non-steroidal compounds |
US10736848B2 (en) * | 2007-10-12 | 2020-08-11 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US20090098118A1 (en) * | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
CA2708223A1 (en) | 2007-12-06 | 2009-06-11 | Andrew Krivoshik | Oral compositions of abt-263 for treating cancer |
CN101220008B (zh) | 2008-01-21 | 2011-04-27 | 中国科学院广州生物医药与健康研究院 | 化合物abt-263的合成方法 |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
US8728516B2 (en) | 2009-04-30 | 2014-05-20 | Abbvie Inc. | Stabilized lipid formulation of apoptosis promoter |
US8362013B2 (en) | 2009-04-30 | 2013-01-29 | Abbvie Inc. | Salt of ABT-263 and solid-state forms thereof |
US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
US8546399B2 (en) | 2009-05-26 | 2013-10-01 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
JP2012530704A (ja) | 2009-06-18 | 2012-12-06 | アボット・ラボラトリーズ | 安定なナノ粒子状薬物懸濁液 |
RU2551376C2 (ru) | 2009-09-20 | 2015-05-20 | Эббви Инк. | Кристаллические формы и сольваты авт-263 для применения в лечении заболеваний, связанных с белком bcl-2 |
CN101798292A (zh) | 2010-03-29 | 2010-08-11 | 无锡好芳德药业有限公司 | ABT-263衍生的新型Bcl-2蛋白抑制剂的制备 |
-
2010
- 2010-04-29 US US12/770,174 patent/US8728516B2/en not_active Expired - Fee Related
- 2010-04-30 TW TW099113990A patent/TW201100125A/zh unknown
- 2010-04-30 MX MX2011011525A patent/MX2011011525A/es active IP Right Grant
- 2010-04-30 RU RU2011148516/15A patent/RU2530642C2/ru not_active IP Right Cessation
- 2010-04-30 NZ NZ596047A patent/NZ596047A/xx not_active IP Right Cessation
- 2010-04-30 SG SG2011073624A patent/SG175145A1/en unknown
- 2010-04-30 JP JP2012508759A patent/JP5788869B2/ja not_active Expired - Fee Related
- 2010-04-30 AR ARP100101469A patent/AR076511A1/es unknown
- 2010-04-30 TW TW104144761A patent/TW201628601A/zh unknown
- 2010-04-30 KR KR1020117028613A patent/KR20120027283A/ko not_active Application Discontinuation
- 2010-04-30 EP EP10717961A patent/EP2424499A1/en not_active Withdrawn
- 2010-04-30 MY MYPI2011005143A patent/MY160603A/en unknown
- 2010-04-30 CN CN201080029687.1A patent/CN102802605B/zh not_active Expired - Fee Related
- 2010-04-30 UY UY0001032601A patent/UY32601A/es not_active Application Discontinuation
- 2010-04-30 CA CA2758596A patent/CA2758596A1/en not_active Abandoned
- 2010-04-30 WO PCT/US2010/033075 patent/WO2010127193A1/en active Application Filing
- 2010-04-30 AU AU2010242926A patent/AU2010242926B2/en not_active Ceased
- 2010-04-30 PE PE2011001864A patent/PE20120642A1/es not_active Application Discontinuation
- 2010-04-30 BR BRPI1014492A patent/BRPI1014492A8/pt not_active IP Right Cessation
-
2011
- 2011-10-02 IL IL215474A patent/IL215474A/en not_active IP Right Cessation
- 2011-10-17 ZA ZA2011/07594A patent/ZA201107594B/en unknown
- 2011-10-25 CL CL2011002652A patent/CL2011002652A1/es unknown
- 2011-10-25 DO DO2011000325A patent/DOP2011000325A/es unknown
- 2011-11-25 CO CO11162226A patent/CO6470833A2/es active IP Right Grant
- 2011-11-29 EC EC2011011491A patent/ECSP11011491A/es unknown
Also Published As
Publication number | Publication date |
---|---|
RU2530642C2 (ru) | 2014-10-10 |
ECSP11011491A (es) | 2011-12-30 |
WO2010127193A1 (en) | 2010-11-04 |
US8728516B2 (en) | 2014-05-20 |
CO6470833A2 (es) | 2012-06-29 |
BRPI1014492A8 (pt) | 2017-10-24 |
IL215474A (en) | 2015-06-30 |
PE20120642A1 (es) | 2012-06-24 |
BRPI1014492A2 (pt) | 2016-04-05 |
SG175145A1 (en) | 2011-11-28 |
KR20120027283A (ko) | 2012-03-21 |
RU2011148516A (ru) | 2013-06-10 |
NZ596047A (en) | 2013-11-29 |
ZA201107594B (en) | 2014-03-26 |
JP5788869B2 (ja) | 2015-10-07 |
US20100278905A1 (en) | 2010-11-04 |
CN102802605A (zh) | 2012-11-28 |
EP2424499A1 (en) | 2012-03-07 |
DOP2011000325A (es) | 2011-11-15 |
CN102802605B (zh) | 2015-08-12 |
MY160603A (en) | 2017-03-15 |
CA2758596A1 (en) | 2010-11-04 |
TW201100125A (en) | 2011-01-01 |
AU2010242926B2 (en) | 2014-04-24 |
AU2010242926A1 (en) | 2011-11-10 |
IL215474A0 (en) | 2011-12-29 |
CL2011002652A1 (es) | 2012-04-20 |
MX2011011525A (es) | 2011-11-18 |
UY32601A (es) | 2010-12-31 |
TW201628601A (zh) | 2016-08-16 |
JP2012525435A (ja) | 2012-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR076511A1 (es) | Composicion farmaceutica en lipidos estabilizada de un promotor de la apoptosis. uso. | |
ES2648037T3 (es) | Preparación oral que comprende un ácido orgánico específico y método para mejorar la propiedad de disolución y la estabilidad química de la preparación oral | |
ES2528793T3 (es) | Compuestos para inhibir la progresión mitótica | |
AR048232A1 (es) | Piperidinilcarbonil- pirrolidinas y su uso como agonistas de melanocortina cr4 | |
AR041635A1 (es) | Compuestos de 4-piperazinilbencenosulfonilindoles, preparacion de los mismos y composiciones farmaceuticas que los contienen | |
AR076859A1 (es) | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. | |
CO6220840A2 (es) | Formulaciones para el tratamiento de cancer | |
AR077393A1 (es) | Composicion farmaceutica para un inhibidor de proteasa del virus de la hepatitis c | |
AR054551A1 (es) | Metodos para la neuroproteccion | |
PE20141702A1 (es) | Compuestos de carbamato y preparacion y uso de los mismos | |
AR048642A1 (es) | Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento | |
AR065499A1 (es) | Inhibidores de serino proteasas.composiciones farmaceuticas | |
PE20140626A1 (es) | Compuestos de bis(fluoroalquil)-1,4-benzodiazepinona | |
AR084312A1 (es) | Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas | |
AR066799A1 (es) | Antagonistas para el receptor ccr2 y sus usos | |
AR060609A1 (es) | Compuestos inhibidores de proteinquinasas c-fms. | |
AR057864A1 (es) | Compuestos de cromano | |
AR078756A1 (es) | Moduladores alostericos positivos (map) | |
AR065464A1 (es) | Derivados de nicotinamida. composiciones farmaceuticas | |
AR068976A1 (es) | Derivados de 2-[2-(fenil)etilamino]alcanoamida substituidos | |
AR069400A1 (es) | 5-[(3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino]-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiinflamatorios | |
AR074353A1 (es) | Acidos naftalen-2-il-aceticos sustituidos, composiciones farmaceuticas que los contienen, y uso de los mismos en el tratamiento de enfermedades alergicas,tales como rinitis, asma y dermatititis atopica. | |
ES2518316T3 (es) | Compuestos heterocíclicos, métodos de fabricación de los mismos y su uso en terapia | |
PE20080055A1 (es) | Dimeros de derivados de artemisinina y su preparacion | |
RU2015107303A (ru) | Соединения и композиции, активирующие ферменты |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |